ArticleBritish journal of clinical pharmacology2007
Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.
Article in British journal of clinical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- Suitability of new drugs registered in Brazil from 2003 to 2013 for pediatric age groups.Einstein (Sao Paulo, Brazil) · 2018Article
- Illicit Internet availability of drugs subject to recall and patient safety consequences.International journal of clinical pharmacy · 2015Article
- The availability and age-appropriateness of medicines authorized for children in The Netherlands.British journal of clinical pharmacology · 2011Article
- Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007.Pharmacy world & science : PWS · 2010Article
- Access to prescribing information for paediatric medicines in the USA: post-modernization.British journal of clinical pharmacology · 2009Article
- Paediatric clinical pharmacology: at the beginning of a new era.European journal of clinical pharmacology · 2008Article
- Availability of pediatric-evaluated formulations in Serbia.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine changes in the availability, in terms of licensing and formulations, of medicines for children in the UK between 1998 and 2002.
methodsUsing the Association of British Pharmaceutical Industry (ABPI) Compendium of Data Sheets and Summaries of Product Characteristics (SPC) 1998 and the Medicines Compendium 2002, licensed medicines available in the UK in the calendar years 1998 and 2002 were examined.
resultsIn 1998, 61% of chemical entities/fixed-dose combinations were licensed in some form for children compared with 64% in 2002. Of the chemical entities/fixed-dose combinations with oral formulations, 250 (33%) in 1998 had an oral formulation suitable for use by children and in 2002 there were 284 (34%). Of the 129 new chemical entities registered in the UK between 1998 and 2002, only 30 (23%) were licensed for under the age of 12 years and 19 (15%) for the neonatal age group. A total of 480 medicines licensed for children were withdrawn from marketing but only cisapride and primidone had no generic or therapeutic alternatives.
conclusionAlthough there was improvement in the availability of medicines for children in the UK over the 5-year period (1998-2002), considerable inequities still existed between children and adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.